var data={"title":"Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6095?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-patient-drug-information\" class=\"drug drug_patient\">see &quot;Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Patient drug information&quot;</a> and <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164442\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vaniqa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3011945\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vaniqa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164459\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiprotozoal;</li>\n      <li>\n        Topical Skin Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164445\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial hair reduction (females):</b> Topical: Apply thin layer to affected areas of face and areas under the chin twice daily, at least 8 hours apart</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of infections caused by <i>Trypanosoma brucei gambiense </i>infection (sleeping sickness) (off-label use):</b> IV infusion: 100 mg/kg/dose given every 6 hours for 14 days (Kappagoda 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164454\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Facial hair reduction (females):</b> Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164446\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164447\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Dose should be adjusted although no specific guidelines are available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50782429\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Dose should be adjusted although no specific guidelines are available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164426\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vaniqa: 13.9% (45 g) [contains cetearyl alcohol, methylparaben, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164411\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15837501\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Injectable eflornithine is donated to World Health Organization (WHO) by the manufacturer. Further information may be found on WHO website at http://www.who.int/trypanosomiasis_african/diagnosis/en/index.html or by contacting the CDC Drug Service (404-639-3670). Additional information from the CDC is available at https://www.cdc.gov/laboratory/drugservice/formulary.html.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164428\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: For external use only. Apply a thin layer to the affected areas of the face and chin; rub in thoroughly. Hair removal techniques must still be continued; wait at least 5 minutes after removing hair to apply cream. Do not wash affected area for at least 4 hours following application. Makeup and sunscreen may be used over treated area(s) after cream has dried.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administered IV only; dilute prior to use and infuse over 45 to 120 minutes. Not for IM administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164427\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Facial hair reduction:</b> Reduce unwanted hair in females from the face and adjacent areas under the chin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725543\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Meningoencephalitic stage of Trypanosoma brucei gambiense infection (sleeping sickness)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164466\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vaniqa may be confused with Viagra</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164418\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection (Priotto 2009):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia (22%), hypertension (13%), chest pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (46%), dizziness (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (19%), skin rash (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (30%), diarrhea (29%), nausea (20%), vomiting (20%), anorexia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (2% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;30%), myalgia (&le;30%), weakness (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (43%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (4%), hypotension (&le;3%), shock (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (10%), seizure (9%), anxiety (8%), peripheral neuropathy (1% to 4%), coma (2%), amnesia (1%), ataxia (1%), confusion (1%), depression (1%), hallucination (1%), lethargy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysphagia (9%), xerostomia (5%), constipation (4%), dysgeusia (2%), hiccups (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary frequency (&le;4%), urinary urgency (&le;4%), urinary incontinence (3%), change in creatinine (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (9%), leukopenia (4%), thrombocytopenia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal bilirubin levels (5%), increased serum transaminases (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Extravasation (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Inner ear disturbance (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (10%), epistaxis (2%), dyspnea (1%), respiratory distress (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Topical:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Dermatologic: Acne vulgaris (11% to 21%), pseudofolliculitis barbae (5% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4%), tingling of skin (2% to 4%), dizziness (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Stinging of the skin (4% to 8%), burning sensation of skin (4%), pruritus (3% to 4%), skin rash (2% to 3%), xeroderma (2% to 3%), erythema (1% to 3%), alopecia (1% to 2%), skin irritation (1% to 2%), folliculitis (&le;1%), ingrown hair (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (2% to 3%), anorexia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acne rosacea, cheilitis, contact dermatitis, dermal hemorrhage, facial edema, herpes simplex infection, nausea, numbness, swelling of lips, vertigo, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164431\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to eflornithine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164415\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cream: Appropriate use: For topical use by females only; discontinue if hypersensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: For IV use only; not for IM administration. Must be diluted before use; frequent monitoring for myelosuppression should be done; use with caution in patients with a history of seizures and in patients with renal impairment; serial audiograms should be obtained; due to the potential for relapse, patients should be followed up for at least 24 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299255\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164420\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9404&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164422\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164434\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">When administered topically, teratogenic effects were not observed in animal reproduction studies. Discontinuation or not initiating therapy should be considered since information related to topical use in pregnancy is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617083\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if eflornithine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering eflornithine to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164424\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with platelet counts</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164414\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: Eflornithine inhibits the enzyme ornithine decarboxylase (ODC) which inhibits cell division and synthetic functions and thereby affects the rate of hair growth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Eflornithine exerts antitumor and antiprotozoal effects through specific, irreversible (&ldquo;suicide&rdquo;) inhibition of the enzyme ornithine decarboxylase (ODC). ODC is the rate-limiting enzyme in the biosynthesis of putrescine, spermine, and spermidine, the major polyamines in nucleated cells. Polyamines are necessary for the synthesis of DNA, RNA, and proteins and are, therefore, necessary for cell growth and differentiation. Although many microorganisms and higher plants are able to produce polyamines from alternate biochemical pathways, all mammalian cells depend on ornithine decarboxylase to produce polyamines. Eflornithine inhibits ODC and rapidly depletes animal cells of putrescine and spermidine; the concentration of spermine remains the same or may even increase. Rapidly dividing cells appear to be most susceptible to the effects of eflornithine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164430\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Decreased hair growth: 4-8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Decreased hair growth: Continues until ~8 weeks after discontinuing treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Topical: &lt;1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 3-3.5 hours; Topical: 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164433\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Vaniqa External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.9% (45 g): $199.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164435\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vaniqa (AU, BE, CZ, DE, DK, ES, FR, GB, HR, HU, IE, IL, IS, IT, LB, LT, MT, NL, NO, NZ, PL, PT, RO, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; <i>Med Lett Drugs Ther</i>, 1993, 35(911):111-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/8246830/pubmed\" target=\"_blank\" id=\"8246830\">8246830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haegele KD, Alken RG, Grove J, et al, &ldquo;Kinetics of &alpha;-Difluoromethylornithine: An Irreversible Inhibitor of Ornithine Decarboxylase,&rdquo; <i>Clin Pharmacol Ther</i>, 1981, 30(2):210-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/6788425/pubmed\" target=\"_blank\" id=\"6788425\">6788425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21628620\"></a>Kappagoda S, Singh U, and Blackburn BG, &quot;Antiparasitic Therapy,&quot; <i>Mayo Clin Proc</i>, 2011, 86(6):561-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/21628620/pubmed\" target=\"_blank\" id=\"21628620\">21628620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapidoth M, Dierickx C, Lanigan S, et al, &quot;Best Practice Options for Hair Removal in Patients With Unwanted Facial Hair Using Combination Therapy With Laser: Guidelines Drawn Up by an Expert Working Group,&quot; <i>Dermatology</i>, 2010, 221(1):34-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/20587996/pubmed\" target=\"_blank\" id=\"20587996\">20587996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1355219\"></a>Milord F, P&eacute;pin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. <i>Lancet</i>. 1992;340(8820):652-655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/1355219/pubmed\" target=\"_blank\" id=\"1355219\">1355219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19559476\"></a>Priotto G, Kasparian S, Mutombo W, et al, &quot;Nifurtimox-Eflornithine Combination Therapy for Second-Stage African <i>Trypanosoma brucei gambiense</i> Trypanosomiasis: A Multicenter, Randomized, Phase III, Non-Inferiority Trial,&quot; <i>Lancet</i>, 2009, 374(9683):56-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/19559476/pubmed\" target=\"_blank\" id=\"19559476\">19559476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20219092\"></a>Steverding D, &quot;The Development of Drugs for Treatment of Sleeping Sickness: A Historical Review,&quot; <i>Parasit Vectors</i>, 2010, 3(1):15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information/abstract-text/20219092/pubmed\" target=\"_blank\" id=\"20219092\">20219092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vaniqa (eflornithine) [prescribing information]. Irvine, CA: Allergan, Inc; September 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9404 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164442\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3011945\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F164459\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F164445\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F164454\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F164446\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F164447\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50782429\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164426\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F164411\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F15837501\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F164428\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F164427\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725543\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F164466\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164418\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164431\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164415\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299255\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F164420\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F164422\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F164434\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617083\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F164424\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164414\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F164430\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F164433\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F164435\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9404|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-patient-drug-information\" class=\"drug drug_patient\">Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Patient drug information</a></li><li><a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information\" class=\"drug drug_pediatric\">Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Pediatric drug information</a></li></ul></div></div>","javascript":null}